ASH 2019: Dr. John Allan on Richter’s Transformation in CLL (chronic lymphocytic leukemia) Dr John Allan on new ways to target Richter’s Transformation.... January 19, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Brian Koffman Interviewed by Zack Pemberton-Whiteley, Leukaemia Care, UK Our own Dr. Koffman was interviewed at ASH 2019 about importance of attending ASH for advocates, his own research, his... January 19, 20202019 ConferencesBy Brad Hedrick
iwCLL 2019: Dr. Jan Burger on targeting the B cell receptor (BCR) in chronic lymphocytic leukemia (CLL) Dr. Burger at iwCLL 2019, discusses the importance of the B cell receptor and blocking it in CLL.... January 6, 20202019 ConferencesBy Brad Hedrick
iwCLL 2019: Dr. Danielle Brander on Bendamustine and Rituxan (BR) versus Ibrutinib Based Therapies for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL) in Elderly Patients The phase III Alliance A041202 collaborative multi-centered trial demonstrated once and for all the superiority of ibrutinib versus Bendamustine/Rituximab (BR)... January 2, 20202019 ConferencesBy Brad Hedrick
ASCO 2019: Pick #1 RESONATE: 6 year follow-up in previously treated CLL (chronic lymphocytic leukemia) on ibrutinib Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his... December 24, 20192019 ConferencesBy Brad Hedrick
ASCO 2019: Pick #2 Fixed duration Venetoclax + Obinutuzumab in untreated CLL (chronic lymphocytic leukemia) Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his... December 24, 20192019 ConferencesBy Brad Hedrick
ACSO 2019: Dr. Koffman’s Pick #3 Acalabrutinib in ibrutinib-intolerant relapsed/refractory chronic lymphocytic leukemia (CLL) Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his... December 22, 20192019 ConferencesBy Brad Hedrick
ASCO 2019: Pick #4 Duvelisib: Effects of Dose modifications in relapsed/ refractory (R/R) chronic lymphocytic leukemia (CLL) Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his... December 22, 20192019 ConferencesBy Brad Hedrick
ASCO 2019: Dr. Koffman’s Pick #6: Acalabrutinib with Obinutuzumab for chronic lymphocytic leukemia (CLL) Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his... December 16, 20192019 ConferencesBy Brad Hedrick
ASCO 2019: Dr. Koffman’s Pick #5 MRD Negative Responses after Liso-Cel or JCAR017 in chronic lymphocytic leukemia (CLL) Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his... December 16, 20192019 ConferencesBy Brad Hedrick
